Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Sorafen A in Ischemic Brain Injury

An ischemic brain injury, ischemic technology, applied in the field of medicine and biology, can solve the problem of limited treatment time window

Inactive Publication Date: 2019-07-19
李佩盈
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the treatment time window of rt-PA is very limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Sorafen A in Ischemic Brain Injury
  • Application of Sorafen A in Ischemic Brain Injury
  • Application of Sorafen A in Ischemic Brain Injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1 Sorafen-A has a neuroprotective effect on acute ischemic brain injury caused by middle cerebral artery occlusion

[0066] experimental method:

[0067] 1) Select male C57 / BL6 wild-type mice (purchased from Shrek Experimental Animal Company) at 8-12 weeks, and randomly divide them into 5 groups, Sham group (n=8), DMSO group (n=8), SorA-1 group (n=8), SorA-5 group (n=8), Sor-A-25 group (n=8).

[0068] 2) Animal models were established with mice in each group. The mice in the Sham group were sham-operated, blood vessels were separated, and no sutures were inserted. Mice in DMSO and three dose groups of SorA underwent middle cerebral artery occlusion (MCAO). The procedure of MCAO operation is as follows: mice were anesthetized with 1.5% isoflurane, and fixed in supine position. The neck was exposed, the median incision was about 3 cm, the trachea was bluntly dissected, the trachea was exposed, the thyroid glands on both sides were bluntly dissected, and the tri...

Embodiment 2

[0076] Example 2 Sorafen-A can improve long-term neurological function after ischemic brain injury

[0077] This study employs a series of robust, sensitive, and reproducible behavioral assays in rodents to assess neurological deficits following ischemic brain injury. All assessment methods were tested weekly starting 1 week after MCAO surgery or sham surgery.

[0078] 1) Corner test: Corner test can detect sensorimotor impairment up to 90 days after MCAO. Place the experimental animal at the entrance of the splint at 30°, and make it move toward the corner by itself. When the mouse advances to the head end of the clip angle, it will turn left or right, then take the mouse out and put it back at the splint entrance, and repeat the above steps. Each mouse was given 10 opportunities to turn forward, and the number of turns to the left was recorded as an evaluation index for the corner test.

[0079] 2) Staggered step test: used to evaluate the function of forelimbs and hindli...

Embodiment 3

[0102] Example 3 Sorafen-A can prevent neurological damage after ischemic brain injury (or ischemic neuron)

[0103] Select 8-12 week male C57 / BL6 wild-type mice (purchased from Shrek Experimental Animal Company), and randomly divide them into 3 groups, Sham group (n=8), DMSO group (n=8), SorA group (n=8 ). The SorA group was given 1mg / kg / d, intraperitoneally injected, and received Sham or MCAO operation after 3 days of pretreatment.

[0104] 3 days, 5 days, 7 days, 14 days, and 28 days after operation, animal behavior tests were performed. The method is the same as above. The mice were sacrificed 3 days after the operation, and the brains were collected for NeuN immunofluorescence staining after perfusion to determine the survival status of neurons.

[0105] The experimental results showed that the survival neurons in the ischemic area of ​​the mice pre-administered Sorafen-A were significantly more than those of the DMSO control mice, see Figure 8 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of Sola A in ischemic brain damage. Specifically, the invention discloses (I) the usage of the Sola A in producing a pharmaceutical composition used to prevent and / or treat ischemic brain damage and / or (II) the function of the Sola A in preparing a pharmaceutical composition used to protect ischemic neuron. According to experiments, Sola A can effectively control the development of acute brain death, reduce infarct size and slow down neuronal edema and angioedema. The Sola A also plays an positive part in protecting neurological functions for a long time.

Description

technical field [0001] The invention relates to the field of medical biology. Specifically, the present invention relates to the new application of the antineoplastic drug Sorafen A in ischemic brain injury. Background technique [0002] The latest national cause of death survey shows that ischemic brain injury (cerebral ischemic injury) or ischemic stroke (ischemic stroke) has jumped to the first cause of disability and death in my country, and the incidence is increasing year by year. . Acute ischemic stroke is the most common type of stroke, accounting for 60% to 80% of all strokes. But at present, there is only recombinant tissue plasminogen activator (recombinant tissue-plasminogen activator, rt-PA) that has a definite therapeutic effect on acute stroke. Rt-PA is currently the only drug approved by the US Food and Drug Administration (US FDA) for the treatment of acute stroke. However, the treatment time window of rt-PA is very limited. In order to avoid cerebral he...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/365A61P9/10A61P25/00
CPCA61K31/365
Inventor 李佩盈俞卫峰杨立群高艳琴蔡梦飞王龙周雨曦陈江龙陈雪梅焦英甫甘愉
Owner 李佩盈
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com